96 related articles for article (PubMed ID: 20635385)
1. A novel mucosal orthotopic murine model of human papillomavirus-associated genital cancers.
Decrausaz L; Gonçalves AR; Domingos-Pereira S; Pythoud C; Stehle JC; Schiller J; Jichlinski P; Nardelli-Haefliger D
Int J Cancer; 2011 May; 128(9):2105-13. PubMed ID: 20635385
[TBL] [Abstract][Full Text] [Related]
2. Induction of human papillomavirus oncogene-specific CD8 T-cell effector responses in the genital mucosa of vaccinated mice.
Decrausaz L; Revaz V; Bobst M; Corthésy B; Romero P; Nardelli-Haefliger D
Int J Cancer; 2010 May; 126(10):2469-78. PubMed ID: 19816937
[TBL] [Abstract][Full Text] [Related]
3. Parenteral is more efficient than mucosal immunization to induce regression of human papillomavirus-associated genital tumors.
Decrausaz L; Domingos-Pereira S; Duc M; Bobst M; Romero P; Schiller JT; Jichlinski P; Nardelli-Haefliger D
Int J Cancer; 2011 Aug; 129(3):762-72. PubMed ID: 21384340
[TBL] [Abstract][Full Text] [Related]
4. Intravaginal Administration of Fc-Fused IL7 Suppresses the Cervicovaginal Tumor by Recruiting HPV DNA Vaccine-Induced CD8 T Cells.
Choi YW; Kang MC; Seo YB; Namkoong H; Park Y; Choi DH; Suh YS; Lee SW; Sung YC; Jin HT
Clin Cancer Res; 2016 Dec; 22(23):5898-5908. PubMed ID: 27407095
[TBL] [Abstract][Full Text] [Related]
5. Honeybee venom possesses anticancer and antiviral effects by differential inhibition of HPV E6 and E7 expression on cervical cancer cell line.
Kim YW; Chaturvedi PK; Chun SN; Lee YG; Ahn WS
Oncol Rep; 2015 Apr; 33(4):1675-82. PubMed ID: 25633640
[TBL] [Abstract][Full Text] [Related]
6. Successful therapeutic vaccination with integrase defective lentiviral vector expressing nononcogenic human papillomavirus E7 protein.
Grasso F; Negri DR; Mochi S; Rossi A; Cesolini A; Giovannelli A; Chiantore MV; Leone P; Giorgi C; Cara A
Int J Cancer; 2013 Jan; 132(2):335-44. PubMed ID: 22700466
[TBL] [Abstract][Full Text] [Related]
7. Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine.
Welters MJ; Kenter GG; Piersma SJ; Vloon AP; Löwik MJ; Berends-van der Meer DM; Drijfhout JW; Valentijn AR; Wafelman AR; Oostendorp J; Fleuren GJ; Offringa R; Melief CJ; van der Burg SH
Clin Cancer Res; 2008 Jan; 14(1):178-87. PubMed ID: 18172269
[TBL] [Abstract][Full Text] [Related]
8. Suppression of tumorigenesis by transcription units expressing the antisense E6 and E7 messenger RNA (mRNA) for the transforming proteins of the human papilloma virus and the sense mRNA for the retinoblastoma gene in cervical carcinoma cells.
Hu G; Liu W; Hanania EG; Fu S; Wang T; Deisseroth AB
Cancer Gene Ther; 1995 Mar; 2(1):19-32. PubMed ID: 7621252
[TBL] [Abstract][Full Text] [Related]
9. High-risk human papillomavirus E7 oncoprotein detection in cervical squamous cell carcinoma.
Ressler S; Scheiden R; Dreier K; Laich A; Müller-Holzner E; Pircher H; Morandell D; Stein I; Viertler HP; Santer FR; Widschwendter A; Even J; Jansen-Dürr P; Capesius C; Zwerschke W
Clin Cancer Res; 2007 Dec; 13(23):7067-72. PubMed ID: 18056184
[TBL] [Abstract][Full Text] [Related]
10. Vaccination with an adenoviral vector expressing calreticulin-human papillomavirus 16 E7 fusion protein eradicates E7 expressing established tumors in mice.
Gomez-Gutierrez JG; Elpek KG; Montes de Oca-Luna R; Shirwan H; Sam Zhou H; McMasters KM
Cancer Immunol Immunother; 2007 Jul; 56(7):997-1007. PubMed ID: 17146630
[TBL] [Abstract][Full Text] [Related]
11. Circulating human papillomavirus type 16 specific T-cells are associated with HLA Class I expression on tumor cells, but not related to the amount of viral oncogene transcripts.
de Boer MA; Jordanova ES; van Poelgeest MI; van den Akker BE; van der Burg SH; Kenter GG; Fleuren GJ
Int J Cancer; 2007 Dec; 121(12):2711-5. PubMed ID: 17724722
[TBL] [Abstract][Full Text] [Related]
12. Eradication of large tumors expressing human papillomavirus E7 protein by therapeutic vaccination with E7 fused to the extra domain a from fibronectin.
Mansilla C; Berraondo P; Durantez M; Martínez M; Casares N; Arribillaga L; Rudilla F; Fioravanti J; Lozano T; Villanueva L; Sarobe P; Borrás F; Leclerc C; Prieto J; Lasarte JJ
Int J Cancer; 2012 Aug; 131(3):641-51. PubMed ID: 21898393
[TBL] [Abstract][Full Text] [Related]
13. Optimal induction of HPV DNA vaccine-induced CD8+ T cell responses and therapeutic antitumor effect by antigen engineering and electroporation.
Seo SH; Jin HT; Park SH; Youn JI; Sung YC
Vaccine; 2009 Sep; 27(42):5906-12. PubMed ID: 19651174
[TBL] [Abstract][Full Text] [Related]
14. A novel, broad spectrum therapeutic HPV vaccine targeting the E7 proteins of HPV16, 18, 31, 45 and 52 that elicits potent E7-specific CD8T cell immunity and regression of large, established, E7-expressing TC-1 tumors.
Wick DA; Webb JR
Vaccine; 2011 Oct; 29(44):7857-66. PubMed ID: 21816200
[TBL] [Abstract][Full Text] [Related]
15. Development and assessment of a general theory of cervical carcinogenesis utilizing a severe combined immunodeficiency murine-human xenograft model.
Tewari KS; Taylor JA; Liao SY; DiSaia PJ; Burger RA; Monk BJ; Hughes CC; Villarreal LP
Gynecol Oncol; 2000 Apr; 77(1):137-48. PubMed ID: 10739703
[TBL] [Abstract][Full Text] [Related]
16. Long-lasting immunoprotective and therapeutic effects of a hyperstable E7 oligomer based vaccine in a murine human papillomavirus tumor model.
Cerutti ML; Alonso LG; Tatti S; de Prat-Gay G
Int J Cancer; 2012 Apr; 130(8):1813-20. PubMed ID: 21780110
[TBL] [Abstract][Full Text] [Related]
17. Can genital-tract human papillomavirus infection and cervical cancer be prevented with a vaccine?
Dillner J; Brown DR
Expert Rev Mol Med; 2004 Apr; 6(9):1-21. PubMed ID: 15096282
[TBL] [Abstract][Full Text] [Related]
18. Genetic immunization against cervical carcinoma: induction of cytotoxic T lymphocyte activity with a recombinant alphavirus vector expressing human papillomavirus type 16 E6 and E7.
Daemen T; Pries F; Bungener L; Kraak M; Regts J; Wilschut J
Gene Ther; 2000 Nov; 7(21):1859-66. PubMed ID: 11110419
[TBL] [Abstract][Full Text] [Related]
19. TA-CIN, a vaccine incorporating a recombinant HPV fusion protein (HPV16 L2E6E7) for the potential treatment of HPV16-associated genital diseases.
Hibbitts S
Curr Opin Mol Ther; 2010 Oct; 12(5):598-606. PubMed ID: 20886392
[TBL] [Abstract][Full Text] [Related]
20. Clonal history of papillomavirus-induced dysplasia in the female lower genital tract.
Vinokurova S; Wentzensen N; Einenkel J; Klaes R; Ziegert C; Melsheimer P; Sartor H; Horn LC; Höckel M; von Knebel Doeberitz M
J Natl Cancer Inst; 2005 Dec; 97(24):1816-21. PubMed ID: 16368943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
